{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:43Z","timestamp":1786991863717,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T00:00:00Z","timestamp":1481328000000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jconrel.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T06:33:25Z","timestamp":1441694005000},"page":"682-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"PB","title":["Diaminosulfide based polymer microparticles as cancer vaccine delivery systems"],"prefix":"10.1016","volume":"220","author":[{"given":"Sean M.","family":"Geary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned B.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-6633","authenticated-orcid":false,"given":"Aliasger K.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.09.002_bb0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles:applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bit.21301","article-title":"Microparticles and nanoparticles for drug delivery","volume":"96","author":"Kohane","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1208\/s12248-014-9676-6","article-title":"Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer","volume":"17","author":"Makkouk","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.2014.851606","article-title":"Tumor lysate-loaded biodegradable microparticles as cancer vaccines","volume":"13","author":"Joshi","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0025","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.biomaterials.2012.12.030","article-title":"Antigen-coated poly alpha-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations","volume":"34","author":"Lemke","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12248-012-9418-6","article-title":"Biodegradable particles as vaccine delivery systems: size matters","volume":"15","author":"Joshi","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2015.03.001","article-title":"Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle","volume":"204","author":"Kai","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.01.010","article-title":"Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms","volume":"201","author":"De Jesus","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2014.11.033","article-title":"In vivo delivery of peptides and toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model","volume":"198","author":"Silva","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/adhm.201200268","article-title":"Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective","volume":"2","author":"Leleux","year":"2013","journal-title":"Adv Healthcare Mater."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2015.03.002","article-title":"Dendrimer-like alpha-d-glucan nanoparticles activate dendritic cells and are effective vaccine adjuvants","volume":"204","author":"Lu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2015.02.006","article-title":"Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation","volume":"203","author":"Rahimian","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2014.07.043","article-title":"Nanoporous polyelectrolyte vaccine microcarriers. A formulation platform for enhancing humoral and cellular immune responses","volume":"195","author":"De Koker","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jconrel.2014.06.027","article-title":"Designing and building the next generation of improved vaccine adjuvants","volume":"190","author":"Brito","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2013.10.032","article-title":"Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles","volume":"173","author":"Li","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0080","doi-asserted-by":"crossref","first-page":"20120939","DOI":"10.1098\/rsif.2012.0939","article-title":"New views on cellular uptake and trafficking of manufactured nanoparticles","volume":"10","author":"Treuel","year":"2013","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0085","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/btpr.10","article-title":"Biomaterials as vaccine adjuvants","volume":"24","author":"Jones","year":"2008","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0090","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1182\/blood-2011-07-367615","article-title":"Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity","volume":"118","author":"Tacken","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1088\/0957-4484\/16\/4\/025","article-title":"Multi-component nanorods for vaccination applications","volume":"16","author":"Salem","year":"2005","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CJI.0b013e31802fd8c6","article-title":"Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles","volume":"30","author":"Zhang","year":"2007","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0105","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1002\/jps.20978","article-title":"A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles","volume":"96","author":"Zhang","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.addr.2008.12.013","article-title":"Innovative strategies for co-delivering antigens and CpG oligonucleotides","volume":"61","author":"Krishnamachari","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0115","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1208\/s12248-014-9624-5","article-title":"Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy","volume":"16","author":"Joshi","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.biomaterials.2014.10.043","article-title":"Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: in vivo tracking and evaluation of antigen-specific CD8+ T cell immune response","volume":"37","author":"Rahimian","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2567.2005.02268.x","article-title":"Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles","volume":"117","author":"Shen","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1126\/science.7809629","article-title":"A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules","volume":"267","author":"Kovacsovics-Bankowski","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/978-1-4939-0345-0_35","article-title":"Production of antigen-loaded biodegradable nanoparticles and uptake by dendritic cells","volume":"1139","author":"Joshi","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12026-014-8537-9","article-title":"Applying biodegradable particles to enhance cancer vaccine efficacy","volume":"59","author":"Ahmed","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0145","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/ma2023167","article-title":"Synthesis of the first poly(diaminosulfide)s and an investigation of their applications as drug delivery vehicles","volume":"45","author":"Yoo","year":"2012","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/02652048.2013.814728","article-title":"Microparticles prepared from sulfenamide-based polymers","volume":"31","author":"D'Mello","year":"2014","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0155","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/ja204116a","article-title":"The \u201cneutral\u201d hydrolysis of simple carboxylic esters in water and the rate enhancements produced by acetylcholinesterase and other carboxylic acid esterases","volume":"133","author":"Wolfenden","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0160","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14760584.2014.852961","article-title":"Therapeutic cancer vaccines: a long and winding road to success","volume":"13","author":"Baxevanis","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030025","article-title":"Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells","volume":"3","author":"Cheng","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0185","first-page":"5260","article-title":"Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrurol.2013.8","article-title":"Proposed mechanisms of action for prostate cancer vaccines","volume":"10","author":"Geary","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067904","article-title":"The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system","volume":"8","author":"Geary","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1189\/jlb.70.6.849","article-title":"Modes of action of Freund's adjuvants in experimental models of autoimmune diseases","volume":"70","author":"Billiau","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","article-title":"Nanoparticle delivery systems in cancer vaccines","volume":"28","author":"Krishnamachari","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0210","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.biomaterials.2004.06.033","article-title":"Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance","volume":"26","author":"Grayson","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0215","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","article-title":"Introduction of soluble protein into the class I pathway of antigen processing and presentation","volume":"54","author":"Moore","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0220","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jps.21840","article-title":"Fabrication, characterization and in vitro evaluation of poly(d,l-lactide-co-glycolide) microparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery","volume":"99","author":"Intra","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00262-011-1038-y","article-title":"Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN","volume":"60","author":"Geary","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0230","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ijc.22873","article-title":"Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine","volume":"121","author":"Karan","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0235","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.vaccine.2008.01.030","article-title":"TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses","volume":"26","author":"Schlosser","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0240","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2015.09.002_bb0245","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bjc.6600814","article-title":"Early detection of tumour immune-rejection using magnetic resonance imaging","volume":"88","author":"Hu","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.09.002_bb0250","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591530105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591530105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T17:33:48Z","timestamp":1691948028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591530105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":50,"alternative-id":["S016836591530105X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.09.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diaminosulfide based polymer microparticles as cancer vaccine delivery systems","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}